<DOC>
	<DOCNO>NCT00153517</DOCNO>
	<brief_summary>The goal study examine acceptability efficacy 2 kind BV treatment among woman low risk preterm delivery . The objective : 1 . To examine side effect patient acceptability oral versus intravaginal metronidazole . 2 . To compare efficacy oral intravaginal metronidazole treatment BV 3 . To study efficacy oral intravaginal metronidazole prevention hospital admission 3rd trimester , chorioamnionitis , preterm delivery , maternal infectious morbidity .</brief_summary>
	<brief_title>Maternal Effects Bacterial Vaginosis ( BV ) Treatment Pregnancy</brief_title>
	<detailed_description>This randomize , placebo-controlled intervention trial . Women diagnose BV+ Gram stain 12-16 week gestation randomly assign follow treatment group : oral metronidazole ( 250 mg TID x 7 day ) intravaginal placebo ; intravaginal metronidazole ( 5g 0.75 % gel BID x 5 day ) oral placebo . African American , Hispanic , Asian/Pacific Islander , Native American , white woman eligible . Women prior preterm delivery , multiple gestation , chronic hypertension pre-existing diabetes , antibiotic use enrollment study , allergy metronidazole , history alcohol abuse past year , woman age 18 exclude .</detailed_description>
	<mesh_term>Birth Weight</mesh_term>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Chorioamnionitis</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>African American , Hispanic , Asian/Pacific Islander , Native American , white woman . Women prior preterm delivery , multiple gestation , chronic hypertension preexist diabetes , antibiotic use enrollment study , allergy metronidazole , history alcohol abuse past year , woman age 18 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Bacterial Vaginosis</keyword>
	<keyword>Metronidazole</keyword>
</DOC>